Prevail focuses on providing a “Line-of Sight” into the Unspoken Emotional Priorities that guide more than 85% of all decisions.
Then Prevail leverages those priorities in the selling conversation and beyond for optimal impact.
Leveraging the Brain Surgery insights into the field force dialogue (salesforce and MSLs) improves emotional engagement which equates into more sales.
There is still an art to marketing.
Information is critical to success and its experience in leveraging nuance that often makes the difference.
Emotional Engagement means customers are sticky. Prevail ensures that Emotional Engagement is always being maximized.
Words Matter: Being able to speak to the customers’ often-unspoken emotional priorities with conversation starters using language that matters to them, ensures customers will listen, think differently and act differently by internalizing messages.
Then understanding how to transition and deal with objections based on the emotional drivers® for choosing the brand, helps marketers and salespeople be as successful as possible.
Slow launch adoption with all generic options.
Highest Rx volume was 5,500 a month.
Implemented PREVAIL™ in Q3.
Script volume increased 142% by the end of Q4.
Sales never over $37M a quarter.
Product in the market for 9 months, then had an adverse event (death) and received a black box label.
Sales were $35MM in Q1, Brain Surgery was hired to chart the course for increasing Emotional Engagement and get them “in-sync”.
Implemented program that leveraged the often-unspoken emotional priorities of the audience in Q3, sales increased 25%.
Full sales training in place by Q4 and sales increased 54% from Q1.
Mature brand facing all generics.
Management received a patient extension so they wanted to see if they could stop the decline.
Highest sales were $66MM a quarter.
Implemented program that leveraged the often-unspoken emotional priorities of the audience in Q3.
Sales increased by 24% Q4 over Q1.
New product that had not gotten momentum.
Leadership needed improved sales velocity.
COVID-19 hits in March and all reps are working remotely.
Implemented program that leveraged the often-unspoken emotional priorities of the audience in Q2.
Sales increased by 7% in Q2 as COVID-19 shut down the US, then increased by 24% in Q3 and another 53% in Q4.
Large unmet need with a crowded competitive landscape (6 launches in the last 2 years).
Asset was the last to launch, so challenging access plus dosing was IV.
Implemented PREVAIL in Q2.
Sales increase in Q2 was 39%, Q3 increase was 28%.
Slow launch adoption with all generic options.
Highest Rx volume was 5,500 a month.
Implemented PREVAIL™ in Q3.
Script volume increased 142% by the end of Q4.
Sales never over $37M a quarter.
Product in the market for 9 months, then had an adverse event (death) and received a black box label.
Sales were $35MM in Q1, Brain Surgery was hired to chart the course for increasing Emotional Engagement and get them “in-sync”.
Implemented program that leveraged the often-unspoken emotional priorities of the audience in Q3, sales increased 25%.
Full sales training in place by Q4 and sales increased 54% from Q1.
Mature brand facing all generics.
Management received a patient extension so they wanted to see if they could stop the decline.
Highest sales were $66MM a quarter.
Implemented program that leveraged the often-unspoken emotional priorities of the audience in Q3.
Sales increased by 24% Q4 over Q1.
New product that had not gotten momentum.
Leadership needed improved sales velocity.
COVID-19 hits in March and all reps are working remotely.
Implemented program that leveraged the often-unspoken emotional priorities of the audience in Q2.
Sales increased by 7% in Q2 as COVID-19 shut down the US, then increased by 24% in Q3 and another 53% in Q4.
Large unmet need with a crowded competitive landscape (6 launches in the last 2 years).
Asset was the last to launch, so challenging access plus dosing was IV.
Implemented PREVAIL in Q2.
Sales increase in Q2 was 39%, Q3 increase was 28%.